Relatlimab/nivolumab
This therapy is a combination of nivolumab and relatlimab-rmbw. Nivolumab inhibits the checkpoint known as programmed death receptor-1 (PD-1), and relatlimab inhibits the checkpoint called lymphocyte activating gene 3 (LAG-3). The use of a combination approach that targets different parts of the immune system helps overcome drug resistance and improve outcomes. For this reason, nivolumab and relatlimab are given together as a single infusion.
It is approved for the treatment of adult and pediatric patients 12 years of age or older (who weigh at least 40 kg or ~88 lbs) with unresectable or metastatic melanoma.
Provider Resources
